0001209191-20-060362.txt : 20201124 0001209191-20-060362.hdr.sgml : 20201124 20201124191250 ACCESSION NUMBER: 0001209191-20-060362 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201120 FILED AS OF DATE: 20201124 DATE AS OF CHANGE: 20201124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kayitalire Louis CENTRAL INDEX KEY: 0001831519 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37718 FILM NUMBER: 201346276 MAIL ADDRESS: STREET 1: C/O EDDEVA B920 STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: F-star Therapeutics, Inc. CENTRAL INDEX KEY: 0001566373 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522386345 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 PARKWOOD DRIVE STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 44 1223 497400 MAIL ADDRESS: STREET 1: 35 PARKWOOD DRIVE STREET 2: BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: Spring Bank Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-20 0 0001566373 F-star Therapeutics, Inc. FSTX 0001831519 Kayitalire Louis C/O F-STAR THERAPEUTICS, INC. EDDEVA B920, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT UNITED KINGDOM 0 1 0 0 Chief Medical Officer Stock Option (right to buy) 16.62 2020-11-20 4 A 0 27289 0.00 A 2029-06-17 Common Stock 27289 27289 D Restricted Stock Units 2020-11-20 4 A 0 26437 0.00 A Common Stock 26437 26437 D This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited. 28% of the options shall vest on the first anniversary of the commencement of employment of the option holder and 2% on the last day of each month subsequent to such first anniversary until the option is fully vested on the fourth anniversary from commencement of employment. Each restricted stock unit represents a contingent right to receive one share of common stock. Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date. /s/ Darlene Deptula-Hicks, Attorney-in-fact 2020-11-24